Company news

Tvardi Therapeutics, Inc. news in 2026

Tvardi Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference

October 14, 2026

Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

August 14, 2026

Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026

August 12, 2026

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

July 29, 2026

Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

July 6, 2026

Tvardi Therapeutics to Participate in Upcoming Investor Events

May 21, 2026

Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update

May 8, 2026

Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium

April 1, 2026

Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update

March 30, 2026

Tvardi Therapeutics to Participate in Upcoming Investor Conferences

February 12, 2026

Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 8, 2026

Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights

January 8, 2026

Decks in 2026